C. Pensec, A. Groh, D. Guenot, L. Calvet, Mignard, O. Duchamp, T. Carton, S. Leuillet, H. Blottiere, F. Le Vacon
Along with 4 other partners, Biofortis Mérieux NutriSciences took part in the conception of the following poster, which was presented in April 2019 at the last American Association for Cancer Research (AACR) annual meeting by Oncodesign, one of the partners of the IMODI (Innovative Models Initiative) project. We remind that the overall aim of IMODI consortium is to accelerate therapeutic innovation and identification of anticancer therapies, with a rapid transfer to the clinic, to the direct benefit of patients. Biofortis is in charge of preclinical and clinical microbiome analysis.
The objectives of this study was to explore, in preclinical models (lung PDX models), the impact of tumor and pemetrexed on:
In the field of lung cancer treatments, significant progresses have been made during the last decade, such as targeted therapies and immunotherapies. Nevertheless, chemotherapy remains the reference treatment for cancer. Pemetrexed is a chemotherapeutic drug commonly used in advanced lung cancer. This drug has a broad-spectrum effect that can induce significant side effects in patients. However, the impact of pemetrexed on gut microbiota and gastrointestinal inflammation in PDX mice remains unknown, although the role of the microbiota in carcinogenesis and modulation of efficacy or toxicity of chemotherapeutic agents has been demonstrated.
This work is a preliminary approach that confirms the relationship between microbiota and chemotherapy. A better understanding of gut microbiota alterations induced by chemotherapy could help reduce side effects. It is essential to expand our knowledge about the chemotherapy impact on microbiota in order to minimize the side effects, avoid infection complications, and improve therapy efficiency.
To learn more about these results, or to ask for a copy of this poster, you may contact us on: email@example.com